The proven leader in left atrial appendage closure
For more than 20 years, WATCHMAN Solutions has led the advancement of LAAC, focusing on clinical evidence and device innovation. Partnering with physicians like you, we’ve helped more than 500,000 patients reduce their atrial fibrillation (AFib)-related stroke risk—without the worry and risks of long term oral anticoagulants (OACs).
The OPTION Clinical Trial: a breakthrough study in AFib treatment
The primary outcomes from the first randomized, head-to-head study comparing the WATCHMAN FLX Device to oral anticoagulants (OACs)—95% of which were direct oral anticoagulants (DOACs)—after cardiac ablation provide pivotal insights into exploring patient alternatives to lifelong oral anticoagulation.1
WATCHMAN TruSteer™ Access System
The WATCHMAN TruSteer Access System improves implant success by optimizing coaxial device positioning in the widest range of LAA anatomies.
The WATCHMAN FLX Pro™ Left Atrial Appendage Device
Introducing three first-ever features to advance performance and safety: new HEMOCOAT™ Technology to improve the healing process, shoulder-level radiopaque markers for precise device placement, and a new 40mm size for larger appendages.
A new chapter: Miguel’s success with the WATCHMAN FLX Pro Device
Follow Miguel’s story to learn how advancements in the WATCHMAN FLX Pro Device made it the clear choice to reduce his stroke risk and help him to live a healthier, fuller life.
Learn more about WATCHMAN Integrated LAAC Solutions
Access resources
Browse the WATCHMAN™ download center for physician and healthcare professional resources.
Stay ahead
Stay ahead with the latest insights, clinical data, and advancements on WATCHMAN Integrated LAAC Solutions.
Connect with us
Contact a local representative to learn more about WATCHMAN Integrated LAAC Solutions.
References:
1. Saliba W, et al. Comparison of Left Atrial Appendage Closure and Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation Concomitant and Sequential Cohorts of the OPTION Randomized Controlled Trial. Late Breaking Clinical Trial, AF Symposium 2025.